Amgen autoimmune drug meets main goal in late-stage trial
Amgen said its experimental autoimmune drug met the main goal of reducing disease activity in a late-stage trial, with shares up 4% in morning trading.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Amgen’s autoimmune drug meets main goal in late-stage trial
Amgen said its experimental autoimmune treatment met the main goal of reducing disease activity in a late-stage trial.